^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    DRD2 expression

    i
    Other names: DRD2, Dopamine Receptor D2, D(2) Dopamine Receptor, Dopamine D2 Receptor, Seven Transmembrane Helix Receptor, Dopamine Receptor D2 Isoform, D2DR, D2R
    Entrez ID:
    1813
    Related biomarkers:
    Expression
    Associations

    News

    Trials
    12ms
    The Activation of p300 Enhances the Sensitivity of Pituitary Adenomas to Dopamine Agonist Treatment by Regulating the Transcription of DRD2. (PubMed, Int J Mol Sci)
    Prolactinomas are commonly treated with dopamine receptor agonists (DAs), such as bromocriptine (BRC) and cabergoline (CAB). These findings highlight the role of p300 in regulating DRD2 transcription in DA-resistant prolactinomas. Combining Tan IIA with BRC may offer a promising strategy to overcome DA resistance.
    Journal
    |
    DRD2 (Dopamine Receptor D2)
    |
    DRD2 expression
    2years
    Hypomethylation of DRD2 promotes breast cancer through the FLNA-ERK pathway. (PubMed, Cancer Genet)
    This study demonstrated the DRD2 promoter region is hypomethylated in hormone-receptor-negative breast cancer or with high-risk factors. The methylation status of the DRD2 promoter and FLNA-ERK signaling pathway and the DRD2 expression in breast cancer treatment need to be considered.
    Journal
    |
    CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • DRD2 (Dopamine Receptor D2)
    |
    HR negative • CD31 expression • DRD2 expression
    2years
    A Study of ONC201 for Refractory Meningioma (clinicaltrials.gov)
    P1, N=27, Suspended, University of Nebraska | Not yet recruiting --> Suspended
    Trial suspension
    |
    DRD2 (Dopamine Receptor D2)
    |
    DRD2 expression
    |
    Modeyso (dordaviprone)
    2years
    Dopamine receptors D1 and D2 show prognostic significance and potential therapeutic applications for endometrial cancer patients. (PubMed, Gynecol Oncol)
    DRD1 and DRD2 expression levels showed a significant association with clinico-pathological parameters. Both the combined activation of DRD1 and blockage of DRD2 may form an innovative strategy to inhibit tumor growth in EC.
    Journal
    |
    ADRB2 (Adrenoceptor Beta 2) • DRD1 (Dopamine Receptor D1) • DRD2 (Dopamine Receptor D2)
    |
    DRD2 expression
    over2years
    A Study of ONC201 for Refractory Meningioma (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, University of Nebraska
    New P1 trial
    |
    DRD2 (Dopamine Receptor D2)
    |
    DRD2 expression
    |
    Modeyso (dordaviprone)
    over2years
    The DRD2 antagonist haloperidol mediates autophagy-induced ferroptosis to increase temozolomide sensitivity by promoting endoplasmic reticulum stress in glioblastoma. (PubMed, Clin Cancer Res)
    Our results provide experimental evidence for repurposing HP as an effective adjunct therapy to inhibit adaptive TMZ resistance in order to enhance the efficacy of chemoradiotherapy in GBM, a strategy that may have broad prospects for clinical application.
    Journal
    |
    DRD2 (Dopamine Receptor D2) • FTH1 (Ferritin Heavy Chain 1)
    |
    DRD2 expression
    |
    temozolomide
    over2years
    Pre-clinical development of a dopamine receptor 2, PD-1, and CD47 trispecific antibody for the treatment of solid tumors (AACR 2023)
    Conventional purification yields 99% purity and notably displays high stability under accelerated stability testing.In conclusion, the trispecific KJ-101 antibody has strong in vivo anti-tumor activity mediated via multiple mechanisms of action, is easily expressed and purified, and is very stable. Together, this data supports the clinical development of KJ-101 in advanced metastatic neuroendocrine cancer indications, including SCLC.
    Preclinical • PD(L)-1 Biomarker • IO biomarker • Trispecific
    |
    PD-1 (Programmed cell death 1) • CD34 (CD34 molecule) • DRD2 (Dopamine Receptor D2) • SIRPA (Signal Regulatory Protein Alpha)
    |
    DRD2 expression
    |
    KJ-101
    over3years
    ONC206 has anti-tumorigenic effects in human ovarian cancer cells and in a transgenic mouse model of high-grade serous ovarian cancer. (PubMed, Am J Cancer Res)
    Our findings demonstrate that ONC206 has anti-tumorigenic effects in ovarian cancer as previously demonstrated by ONC201 but appears to be as well tolerated and more potent. Thus, ONC206 deserves further evaluation in clinical trials.
    Preclinical • Journal
    |
    BCL2L1 (BCL2-like 1) • CLPP (Caseinolytic Mitochondrial Matrix Peptidase Proteolytic Subunit) • DRD2 (Dopamine Receptor D2)
    |
    DRD2 expression
    |
    Modeyso (dordaviprone) • JZP3507
    4years
    The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas. (PubMed, BMC Endocr Disord)
    Bromocriptine reduces the expression of MAPK11/12/13/14 in prolactinomas, and MAPK11 and MAPK14 are involved in bromocriptine resistance in prolactinomas by regulating apoptosis. Reducing the expression of MAPK11 or MAPK14 can reverse bromocriptine resistance in prolactinomas.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • MAPK1 (Mitogen-activated protein kinase 1) • DRD2 (Dopamine Receptor D2) • RELA (RELA Proto-Oncogene)
    |
    DRD2 expression